What is William Blair’s Estimate for CRL Q1 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities research analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Charles River Laboratories International in a report issued on Wednesday, February 19th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $2.06 for the quarter, down from their previous forecast of $2.41. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q3 2025 earnings at $2.44 EPS, Q4 2025 earnings at $2.48 EPS, Q4 2026 earnings at $2.68 EPS and FY2026 earnings at $10.33 EPS.

Other research analysts have also recently issued research reports about the company. Barclays decreased their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 18th. Morgan Stanley decreased their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. UBS Group reaffirmed a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Finally, TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $163.11 on Monday. The firm has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a PEG ratio of 4.54 and a beta of 1.37. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average of $172.84 and a 200 day moving average of $188.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 earnings per share.

Institutional Trading of Charles River Laboratories International

Institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. raised its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International in the fourth quarter worth $37,000. Finally, GeoWealth Management LLC boosted its position in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).